| Literature DB >> 30517108 |
Jaqueline Poleto Bragato1, Larissa Martins Melo1, Gabriela Lovizutto Venturin1, Gabriela Torres Rebech1, Leandro Encarnação Garcia2, Flavia Lombardi Lopes2, Valéria Marçal Felix de Lima1.
Abstract
Visceral leishmaniasis (VL) in humans is a chronic and often fatal disease if left untreated. Dogs appear to be the main reservoir host for L. infantum infection, however, in many regions other canids such as jackals, foxes, wolves and other mammals, such as hares or black rats, have been implicated as wild reservoirs. Most dogs cannot form an effective immune response against this infection, and this could be modulated by small non-coding RNAs, called microRNAs, responsible for post-transcriptional control of gene expression. Here, we evaluated the expression of miRNAs in peripheral blood mononuclear cells (PBMC) of symptomatic dogs naturally infected with Leishmania (L.) infantum (n = 10) and compared to those of healthy dogs (n = 5). Microarray analysis revealed that miR-21, miR-424, miR-194 and miR-451 had a 3-fold increase in expression, miR-192, miR-503, and miR-371 had a 2-fold increase in expression, whereas a 2-fold reduction in expression was observed for miR-150 and miR-574. Real-time PCR validated the differential expression of miR-21, miR-150, miR-451, miR-192, miR-194, and miR-371. Parasite load of PBMC was measured by real-time PCR and correlated to the differentially expressed miRNAs, showing a strong positive correlation with expression of miR-194, a regular positive correlation with miR-371 expression, and a moderate negative correlation with miR-150 expression in PBMC. These findings suggest that Leishmania infection interferes with miRNAs expression in PBMC, and their correlation with parasite load may help in the identification of therapeutic targets in Canine Visceral Leishmaniasis (CVL).Entities:
Mesh:
Substances:
Year: 2018 PMID: 30517108 PMCID: PMC6281177 DOI: 10.1371/journal.pone.0206876
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Differentially expressed miRNAs in PBMC of dogs infected with L. infantum.
(A) Heatmap of differentially expressed miRNAs in PBMC of dogs infected with L. infantum compared to control group. Heatmap shows the average signal of miRNAs. Upregulated miRNAs are plotted in red and downregulated miRNAs are plotted in green. Fold change cut-off was lower than -2 and greater than 2. Analysis of variances (ANOVA) was performed between groups. (B) To the left, in green, are illustrated the miRNAs with negative expression and to the right in red the miRNAs with positive expression compared to control. miRNAs illustrated in grey hybridized, but did not show homology with known canine miRNAs. (C) miRNAs validated by real-time PCR. Expression of microRNAs in infected and healthy groups was quantified by real-time PCR in PBMC of infected and healthy dogs. Data represent the mean values of miRNA expression +/- standard error of the mean, and the asterisks represent statistically significant data following Mann-Whitney test. Results was considered significant when p<0.05.
Top twenty canonical pathways predicted for the differentially regulated miRNAs in CVL.
| Ingenuity Canonical Pathways | P value | miRNAs in the Pathway | Target genes |
|---|---|---|---|
| Aryl Hydrocarbon Receptor Signaling | 0.00014 | miR-150 | CDKN1B, CHEK2, HSP90B1, IL1A, TNF, TP53 |
| miR-192 | ATM, DHFR, FASLG, GSTA2, RB1 | ||
| miR-194 | ALDH4A1, GSTT2, IL1A, MAPK1 | ||
| miR-21 | ALDH1A1, APAF1, CDK6, CDKN1A, FAS, FASLG, IL1B, NFIA, NFIB, TNF | ||
| p53 Signaling | 0.00015 | miR-150 | CHEK2, MDM4, PERP, TP53 |
| miR-192 | ATM, PERP, RB1, STAG1 | ||
| miR-194 | CCNG1, CSNK1D, SERPINE2, THBS1 | ||
| miR-21 | APAF1, CCNG1, CDKN1A, FAS, FRS2, PIK3R1, PTEN, SERPINB5, TNFRSF10B | ||
| Tumoricidal Function of Hepatic Natural Killer Cells | 0.00030 | miR-150 | GZMB |
| miR-192 | CYCS, FASLG | ||
| miR-194 | CASP7, SRGN | ||
| miR-21 | APAF1, CASP8, FAS, FASLG | ||
| Osteoarthritis Pathway | 0.00068 | miR-150 | CEBPB, CREB1, MMP13, TNF, VEGFA |
| miR-192 | ADIPOQ, FGF2, HTRA1, IL1RAP, SDC4, TGFBR1 | ||
| miR-194 | CASP7, FZD6, RAC1 | ||
| miR-21 | BMPR2, CASP8, FGF18, FZD6, GLIS2, IL1B, JAG1, RBPJ, SMAD7, TGFBR2, TIMP3, TNF, VEGFC | ||
| Hepatic Fibrosis / Hepatic Stellate Cell Activation | 0.00098 | miR-150 | IL1A, MMP13, PDGFB, STAT1, TNF, VEGFA |
| miR-192 | CCR5, CSF1, FASLG, FGF2, FLT1, IL1RAP, SERPINE1, TGFBR1 | ||
| miR-194 | CXCL3, EDN1, IL1A | ||
| miR-21 | ACTA2, CCR7, FAS, FASLG, IL1B, IL6R, KLF6, SMAD7, TGFBR2, TNF, TNFRSF11B, VEGFC | ||
| Crosstalk between Dendritic Cells and Natural Killer Cells | 0.00141 | miR-150 | CD226, TNF |
| miR-192 | CD80, FASLG | ||
| miR-194 | ACTG2, CD83, FSCN3 | ||
| miR-21 | ACTA2, CCR7, CD69, FAS, FASLG, IL12A, TNF | ||
| dTMP De Novo Biosynthesis | 0.00182 | miR-192 | DHFR, DHFR2, TYMS |
| Cell Cycle: G1/S Checkpoint Regulation | 0.00186 | miR-150 | CDKN1B, HDAC8, SKP1, TP53 |
| miR-192 | ATM, RB1 | ||
| miR-194 | BMI1, E2F6, HDAC8 | ||
| miR-21 | CDC25A, CDK6, CDKN1A, SKP2 | ||
| STAT3 Pathway | 0.00347 | miR-192 | FLT1, PIM1, SOCS6, TGFBR1 |
| miR-194 | MAPK1, RAC1, RRAS2, SOCS2 | ||
| miR-21 | BMPR2, CDC25A, CDKN1A, MAPK10, SOCS5, SOCS6, STAT3, TGFBR2 | ||
| Human Embryonic Stem Cell Pluripotency | 0.00363 | miR-150 | FOXD3, PDGFB |
| miR-192 | ATM, FGF2, LEFTY2, TGFBR1 | ||
| miR-194 | ACVR1, FZD6, H2BFM | ||
| miR-21 | BMPR2, FRS2, FZD6, NTF3, PIK3R1, SMAD7, SOX2, TGFBR2 | ||
| Estrogen-mediated S-phase Entry | 0.00417 | miR-150 | CDKN1B |
| miR-192 | RB1 | ||
| miR-194 | E2F6 | ||
| miR-21 | CDC25A | ||
| Actin Cytoskeleton Signaling | 0.00427 | miR-150 | ARPC3, FGF16, PDGFB, TMSB4Y |
| miR-192 | ATM, BRK1, CRK, FGF14, FGF2, FGF7, MSN, MYLK, PIP4K2B | ||
| miR-194 | ACTG2, CFL2, GNA13, LIMK2, MAPK1, PFN2, PIP4K2C, RAC1, RRAS2, TMSB4Y | ||
| miR-21 | ACTA2, ARHGAP24, ARHGEF12, CFL2, FGF18, FRS2, PFN2, PIK3R1, SOS2, TIAM1, TMSB4Y | ||
| Type I Diabetes Mellitus Signaling | 0.00427 | miR-150 | GZMB, STAT1, TNF |
| miR-192 | CD80, CYCS, FASLG, GAD1, HLA-DOB, IL1RAP, SOCS6 | ||
| miR-194 | GAD1, MAPK1, SOCS2, TRAF6 | ||
| miR-21 | APAF1, CASP8, FAS, FASLG, IL12A, IL1B, MAP2K3, MAPK10, SOCS5, SOCS6, TNF, TNFRSF11B | ||
| Cyclins and Cell Cycle Regulation | 0.00437 | miR-150 | CDKN1B, HDAC8, SKP1, TP53 |
| miR-192 | ATM, PPP2CB | ||
| miR-194 | E2F6, HDAC8 | ||
| miR-21 | CDC25A, CDK6, CDKN1A, SKP2 | ||
| Regulation of the Epithelial-Mesenchymal Transition Pathway | 0.00468 | miR-150 | FGF16, ZEB1 |
| miR-192 | ATM, FGF14, FGF2, FGF7, TGFBR1, ZEB1, ZEB2 | ||
| miR-194 | FZD6, MAPK1, RRAS2 | ||
| miR-21 | FGF18, FRS2, FZD6, JAG1, MAP2K3, PIK3R1, RBPJ, SOS2, STAT3, TGFBR2 | ||
| Antiproliferative Role of TOB in T Cell Signaling | 0.00525 | miR-150 | CDKN1B, SKP1 |
| miR-192 | PABPC4, RB1, TGFBR1 | ||
| miR-194 | MAPK1 | ||
| miR-21 | SKP2, TGFBR2 | ||
| Molecular Mechanisms of Cancer | 0.00603 | miR-150 | CDKN1B, CHEK2, RAPGEF3, TP53 |
| miR-192 | ATM, CRK, CYCS, FASLG, PRKAR1A, PRKCQ, RALB, RB1, TGFBR1, XIAP | ||
| miR-194 | ADCY7, CASP7, CDK14, E2F6, FNBP1, FZD6, GNA13, H2BFM, MAPK1, PRKAR1A, RAC1, RAP2B, RRAS2 | ||
| miR-21 | APAF1, ARHGEF12, BMPR2, CASP8, CDC25A, CDK6, CDKN1A, FAS, FASLG, FRS2, FZD6, PIK3R1, SMAD7, TGFBR2 | ||
| PTEN Signaling | 0.00603 | miR-150 | CDKN1B |
| miR-192 | FASLG, FLT1, TGFBR1 | ||
| miR-194 | H2BFM, MAPK1, RAC1, RRAS2 | ||
| miR-21 | BMPR2, CDKN1A, FASLG, PIK3R1, PREX2, PTEN, SOS2, TGFBR2 | ||
| Small Cell Lung Cancer Signaling | 0.00631 | miR-150 | CDKN1B, CKS1B, TP53 |
| miR-192 | ATM, CYCS, RB1, TRAF5 | ||
| miR-194 | CKS1B, MAPK1, RRAS2, TRAF6 | ||
| miR-21 | APAF1, CDK6, FRS2, PIK3R1, PTEN, SKP2, SOS2 | ||
| Death Receptor Signaling | 0.00912 | miR-150 | MAP4K4, TNF |
| miR-192 | CYCS, FASLG | ||
| miR-194 | XIAP, ACTG2, CASP7, MAP4K4, PARP11 | ||
| miR-21 | ACTA2, APAF1, CASP8, FAS, FASLG, TNF |
Fig 2IPA’s Canonical Pathway “crosstalk between dendritic cells and natural killer cells”.
Upregulated miRNAs are in red, and downregulated are in green. Indirect relationships are represented by dotted lines and direct relationships by solid lines. miR-290 is a synonym of miR-371 in IPA’s analysis. miR-192 targets CD80 and FASL. miR-371 targets IL-6 and TNF-α. miR-150 targets TNF-α and DNAM-1. miR-21 targets FAS, FASL, TNFα, CD40L, NFκB, IFNγ, CD69 and CCR7. This figure was obtained with Ingenuity Pathway Analysis (Qiagen).
Fig 3Correlation on miRNAs validated by RT-PCR and parasite load in PBMC of dogs infected by L. infantum.
Data represents a negative correlation of miR-150 (A) and positive correlation of miR-194 (B) and miR-371 (C).